Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 12/20 | 0.69 |
| ▸ | CA1 | P00915 | 12/20 | 0.69 |
| ▸ | CA9 | Q16790 | 12/20 | 0.69 |
| ▸ | CA2 | P00918 | 11/20 | 0.69 |
| ▸ | PKM | P14618 | 4/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27792013 | 0.82 | CA12 (1.00) | CA12CA1CA9CA2PKM | |
| SCHEMBL8810276 | 0.80 | CA12 (1.00) | CA12CA1CA9CA2LMNA | |
| SCHEMBL830136 | 0.79 | CA1 (1.00) | CA12CA1CA9CA2RXFP1 | |
| SCHEMBL31287831 | 0.76 | SMN1; SMN2 (0.56) | CA12CA1CA9CA2PKM | |
| SCHEMBL1743537 | 0.76 | SMN1; SMN2 (0.56) | CA12CA1CA9CA2PKM | |
| Furan SCHEMBL1680246 | 0.73 | CA1 (0.85) | CA12CA1CA9CA2RXFP1 | |
| SCHEMBL830157 | 0.71 | CA2 (0.56) | CA12CA1CA9CA2PKM | |
| SCHEMBL21033100 | 0.70 | CA12 (0.68) | CA12CA1CA9CA2PKM | |
| SCHEMBL20435633 | 0.70 | LMNA (0.80) | CA12CA1CA9CA2PKM | |
| SCHEMBL5428747 | 0.69 | GPR27 (0.56) | CA12CA1CA9CA2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143428-B2 | Heteroaryl sulfones and sulfonamides and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1765804-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123077-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | SULT1E1, STS, CCNE1 | CA12 2448/4885CA1 3859/4885CA9 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.